Skip to main content
Marjorie Green, MD, Oncology, Houston, TX

MarjorieGreenMD

Oncology Houston, TX

Breast Cancer, Hematologic Oncology

Associate Professor of Medicine

Dr. Green is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Green's full profile

Already have an account?

  • Office

    1515 Holcombe Blvd
    Houston, TX 77030
    Phone+1 713-792-6161

Education & Training

  • University of Texas Health Science Center at Houston
    University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1998 - 2001
  • University of Virginia Medical Center
    University of Virginia Medical CenterResidency, Internal Medicine, 1995 - 1998
  • University of Texas Medical Branch School of Medicine
    University of Texas Medical Branch School of MedicineClass of 1995

Certifications & Licensure

  • TX State Medical License
    TX State Medical License 2000 - 2024
  • MA State Medical License
    MA State Medical License 1981 - 2017

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Moderna and MSD Begin Trial of mRNA-4157 and Keytruda Combination for Lung Cancer
    Moderna and MSD Begin Trial of mRNA-4157 and Keytruda Combination for Lung CancerOctober 29th, 2024
  • Patritumab Deruxtecan Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Doublet Chemotherapy in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer in HERTHENA-Lung02 Phase 3 Trial
    Patritumab Deruxtecan Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Doublet Chemotherapy in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer in HERTHENA-Lung02 Phase 3 TrialSeptember 17th, 2024
  • Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial
    Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 TrialSeptember 7th, 2024
  • Join now to see all